This protocol was developed for practitioners using Fullscript in Canada and the templates cannot be applied to accounts operating outside of Canada

This protocol supports healthy glucose levels. 

Duration: Reassess in 3–4 months. Patient follow-up is at the discretion of the practitioner.

Ultra Glucose Control®

    • Dosing: 2–3 scoops daily*
    • Description: Ultra Glucose Control® delivers a ratio-balanced combination of carbohydrates, protein, and fat. Formulated with MetaRelease®, a proprietary blend of slow-release carbohydrates known as UCAN SuperStarch®, oat hull fiber, plant proteins, and branched-chain amino acids, Ultra Glucose Control® helps support healthy glucose levels.

Meta Lipoate® 300

    • Dosing: 1 tablet with each meal
    • Description: Meta Lipoate® 300 features high-quality alpha-lipoic acid (ALA) in a convenient, one-tablet dosage of 300 mg. ALA supports healthy antioxidant levels, glucose metabolism, and nervous tissue.*

Berberine GT

    • Dosing: 3 capsules daily
    • Description: Berberine GT features 500 mg of berberine HCl to support healthy glucose and insulin metabolism, fat metabolism, high-density lipoprotein (HDL) cholesterol levels already in the normal range, and triglyceride levels.*

OmegaGenics® EPA DHA 1000

    • Dosing: 2 capsules daily
    • Description: OmegaGenics® EPA-DHA 1000 is a concentrated, purified source of omega-3 fatty acids in triglyceride form from sustainably sourced, cold-water fish. Each softgel provides a total of 710 mg EPA and 290 mg DHA.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Disclaimer

The Fullscript Integrative Medical Advisory team has developed or collected these templates from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this template to your Fullscript template library, you understand and accept that the recommendations in the template are for initial guidance and may not be appropriate for every patient.

View protocol on Fullscript